1. Home
  2. SPRO vs FEAM Comparison

SPRO vs FEAM Comparison

Compare SPRO & FEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Spero Therapeutics Inc.

SPRO

Spero Therapeutics Inc.

SELL

Current Price

$0.94

Market Cap

67.0M

Sector

Health Care

ML Signal

SELL

Logo 5E Advanced Materials Inc.

FEAM

5E Advanced Materials Inc.

HOLD

Current Price

$1.61

Market Cap

56.9M

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
SPRO
FEAM
Founded
2013
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Major Chemicals
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
67.0M
56.9M
IPO Year
2017
2022

Fundamental Metrics

Financial Performance
Metric
SPRO
FEAM
Price
$0.94
$1.61
Analyst Decision
Buy
Buy
Analyst Count
3
2
Target Price
$5.33
★ $5.88
AVG Volume (30 Days)
320.0K
★ 359.6K
Earning Date
11-12-2026
11-17-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 111.81
63.80
EPS
★ N/A
N/A
Revenue
★ $66,802,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$81.81
P/E Ratio
N/A
★ N/A
Revenue Growth
★ 39.24
N/A
52 Week Low
$0.95
$0.90
52 Week High
$3.08
$4.65

Technical Indicators

Market Signals
Indicator
SPRO
FEAM
Relative Strength Index (RSI) 34.32 31.76
Support Level N/A $1.37
Resistance Level $1.27 $1.99
Average True Range (ATR) 0.06 0.20
MACD -0.01 -0.06
Stochastic Oscillator 3.18 3.64

Price Performance

Historical Comparison
SPRO
FEAM

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

About FEAM 5E Advanced Materials Inc.

5E Advanced Materials Inc is an exploration stage company focused on becoming a vertically integrated supplier of specialty boron and boron derivative materials whose mission is to enable decarbonization, increase food security, and ensure domestic supply of critical materials. It has a project located in southern California underpinned by a mineral resource that includes boron and lithium, with the boron being contained in a conventional boron mineral known as colemanite. The company seeks to extract and process the minerals into boric acid, boron materials, lithium carbonate, and potentially other co-products on a commercial scale.

Share on Social Networks: